Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a09ca043d7e596facff1f44b746e2f4d |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 |
filingDate |
2003-09-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_579a55b0384cb108a8f12501a319ffa2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e7672f2c3590afeb282d6c3009e2fb73 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2b5ad677a79a57cceb2a31a7551d2630 |
publicationDate |
2004-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
CA-2497804-A1 |
titleOfInvention |
Human anti-human mcp-1 antibody and fragment of said antibody |
abstract |
It is intended to provide substances efficacious in treating immunopathies in which MCP-1 participates. Using the phage antibody method, scFv having a high affinity for human MCP-1 is obtained. Based on the data concerning the VH chain and the VL chain obtained from this scFv, a human antihuman MCP-1 antibody and a human antihuman MCP-1 antibody fragment are obtained. These antibody and antibody fragment are expected as usable as remedies for inflammation and immunopathies caused by MCP-1. |
priorityDate |
2002-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |